P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
C. Ola Landgren,Ajai Chari,Yael C Cohen,Andrew Spencer,Peter M. Voorhees,Jane Estell,Irwindeep Sandhu,Matthew W Jenner,Catherine D. Williams,Michele Cavo,Niels W.C.J. van de Donk,Meral Beksac,Philippe Moreau,Hartmut Goldschmidt,Steven Kuppens,Rajesh Bandekar,Pamela L. Clemens,Tobias Neff,Christoph Heuck,Ming Qi,Craig C. Hofmeister +20 more
TL;DR: In the CENTAURUS trial as mentioned in this paper, patients with intermediate-risk or high-risk multiple myeloma (SMM) were randomly assigned to daratumumab 16 mg/kg intravenously on extended intense (intense), extended intermediate (intermediate), or short dosing schedules.
Journal ArticleDOI
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
Ghandi Damaj,Florent Malard,C. Hulin,Denis Caillot,Reda Garidi,Bruno Royer,Gerald Marit,Stoppa Am,Anne Banos,Nadine Morineau,Philippe Moreau,Olivier Fitoussi,Mourad Tiab +12 more
TL;DR: Both the response rate and the duration of response are encouraging and indicate that bendamustine presents a feasible option, which should be considered for the treatment of relapsed/refractory patients.
Journal ArticleDOI
How to manage neutropenia in multiple myeloma
Antonio Palumbo,Jon Bladé,Mario Boccadoro,Carmela Palladino,Faith E. Davies,Meletios A. Dimopoulos,Anna Dmoszynska,Hermann Einsele,Philippe Moreau,Orhan Sezer,Andrew Spencer,Pieter Sonneveld,Jesús F. San Miguel +12 more
TL;DR: In patients with multiple myeloma, the novel agents thalidomides, lenalidomide, and bortezomib have improved outcome, but chemotherapy-related neutropenia should be carefully considered, and Granulocyte-colony stimulating factor (G-CSF) should be used to manage chemotherapy- related neutropania.
Journal ArticleDOI
Magneto-active substrates for local mechanical stimulation of living cells
Cécile M. Bidan,Mario Fratzl,Alexis Coullomb,Philippe Moreau,Alain H. Lombard,Irène Wang,Martial Balland,Thomas Boudou,Nora M. Dempsey,Thibaut Devillers,Aurélie Dupont +10 more
TL;DR: In this paper, a magneto-active substrate made of magnetic micro-pillars embedded in an elastomer was used to study the cellular response to an external mechanical stimulation.
Journal ArticleDOI
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A. Dimopoulos,Xavier Leleu,Philippe Moreau,Paul G. Richardson,Anna Marina Liberati,Simon J. Harrison,H. Miles Prince,Enrique M. Ocio,Sylvie Assadourian,Frank Campana,Laure Malinge,Dorothée Semiond,Helgi van de Velde,Kwee Yong +13 more
TL;DR: The addition of Isa to Pd improved PFS, ORR and renal response rates, and Isa pharmacokinetics were comparable between the subgroups, suggesting no need for dose adjustment in patients with RI.